You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,431,685


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,431,685
Title:Polymer-based sustained release device
Abstract: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
Inventor(s): Wright; Steven G. (Madeira, OH), Christensen; Troy (Mason, OH), Yeoh; Thean (Salem, CT), Rickey; Michael E. (Morrow, OH), Hotz; Joyce M. (Cincinnati, OH), Kumar; Rajesh (Marlborough, MA), Costantino; Henry R. (Woodinville, WA)
Assignee: Alkermes Pharma Ireland Limited (Dublin, IE)
Application Number:12/713,036
Patent Claims: 1. An injectable composition for sustained release of a glucoregulatory polypeptide, comprising: a biocompatible polymer having the glucoregulatory polypeptide dispersed therein so as to be present at about 0.5 to 5% (w/w) of the weight of the composition, and a sugar dispersed therein so as to be present at about 0.1 to 5% (w/w) of the weight of the composition, wherein the injectable composition is free from additional ingredients that alter the rate of release of the glucoregulatory polypeptide from the injection composition, and wherein sustained release of the glucoregulatory polypeptide occurs over at least a period of about one week.

2. The injectable composition of claim 1, wherein the sustained release of the glucoregulatory polypeptide occurs over at least a period of about two weeks.

3. The injectable composition of claim 1, wherein the sustained release of the glucoregulatory polypeptide occurs over at least a period of about three weeks.

4. The injectable composition of claim 1, wherein the sustained release of the glucoregulatory polypeptide occurs over at least a period of about four weeks.

5. A method of treating a patient suffering from Type 2 diabetes, comprising administering a therapeutically effective amount of the injectable composition of claim 1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.